1046 related articles for article (PubMed ID: 17766320)
21. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
[TBL] [Abstract][Full Text] [Related]
22. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG
Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388
[TBL] [Abstract][Full Text] [Related]
23. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
24. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
Gintant GA; Su Z; Martin RL; Cox BF
Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
[TBL] [Abstract][Full Text] [Related]
25. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
26. [Proarrhythmic (torsadogenic) effects of QT-prolonging non-antiarrhythmic drugs].
Fazekas T; Liszkai G
Orv Hetil; 2005 Mar; 146(10):451-60. PubMed ID: 15835343
[TBL] [Abstract][Full Text] [Related]
27. Long QT syndrome caused by noncardiac drugs.
Viskin S; Justo D; Halkin A; Zeltser D
Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
[TBL] [Abstract][Full Text] [Related]
28. [Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].
Kecskeméti V
Neuropsychopharmacol Hung; 2004 Mar; 6(1):5-12. PubMed ID: 15125308
[TBL] [Abstract][Full Text] [Related]
29. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes.
Antzelevitch C
Heart Rhythm; 2005 Nov; 2(2 Suppl):S9-15. PubMed ID: 16253930
[TBL] [Abstract][Full Text] [Related]
30. Drug-induced q-T prolongation.
Kao LW; Furbee RB
Med Clin North Am; 2005 Nov; 89(6):1125-44, x. PubMed ID: 16227057
[TBL] [Abstract][Full Text] [Related]
31. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes.
Antzelevitch C
Europace; 2007 Sep; 9 Suppl 4(Suppl 4):iv4-15. PubMed ID: 17766323
[TBL] [Abstract][Full Text] [Related]
32. QT interval prolongation and torsade de pointes associated with indapamide.
Letsas KP; Alexanian IP; Pappas LK; Kounas SP; Efremidis M; Sideris A; Kardaras F
Int J Cardiol; 2006 Oct; 112(3):373-4. PubMed ID: 16260053
[TBL] [Abstract][Full Text] [Related]
33. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability).
Hondeghem LM
Novartis Found Symp; 2005; 266():235-44; discussion 244-50. PubMed ID: 16050272
[TBL] [Abstract][Full Text] [Related]
34. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
35. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
36. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
37. Citalopram induced torsade de pointes, a rare life threatening side effect.
Kanjanauthai S; Kanluen T; Chareonthaitawee P
Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
[TBL] [Abstract][Full Text] [Related]
38. Drug-induced QT dispersion: does it predict the risk of torsade de pointes?
Shah RR
J Electrocardiol; 2005 Jan; 38(1):10-8. PubMed ID: 15660342
[TBL] [Abstract][Full Text] [Related]
39. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
[TBL] [Abstract][Full Text] [Related]
40. Early afterdepolarizations and arrhythmogenesis. Experimental and clinical aspects.
el-Sherif N
Arch Mal Coeur Vaiss; 1991 Feb; 84(2):227-34. PubMed ID: 1708655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
